FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097574458> ?p ?o ?g. }

• W2097574458 endingPage "7764" @default.
• W2097574458 startingPage "7754" @default.
• W2097574458 abstract "Abstract Background: Tivantinib, an oral, non-ATP competitive, selective c-MET inhibitor, exhibited antitumor activity in preclinical models. This open-label, phase I, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of tivantinib in patients with advanced or metastatic solid tumors refractory to standard therapy. Methods: Thirteen dose levels of tivantinib ranging from 10 to 360 mg twice a day were administered to patient cohorts in 21-day cycles (14 days on/7 days off); three active pharmaceutical ingredient forms of tivantinib (amorphous, crystalline A, and crystalline B) were also investigated. Treatment was continued until the occurrence of unacceptable toxicity, tumor progression, patient withdrawal, or death. Results: A total of 79 patients with advanced solid tumors were enrolled. A maximum tolerated dose was not determined. Tivantinib was well tolerated, with mild to moderate toxicities. Two patients discontinued the study drug due to treatment-emergent adverse events. Dose-limiting grade of 3 or more toxicities including leukopenia, neutropenia, thrombocytopenia, vomiting, and dehydration, were observed in 2 patients treated with tivantinib 360 mg twice a day. The rate of absorption of tivantinib peaked approximately 2 to 4 hours after initial dosing, followed by a linear decrease in plasma concentrations. Increases in tivantinib exposure were not dose proportional. There was significant interpatient pharmacokinetic variability; however the clinical safety of tivantinib seemed unaffected. Three patients (3.8%) achieved a partial response and 40 patients (50.6%) maintained stable disease for a median of 19.9 weeks. Conclusions: Tivantinib 360 mg twice a day was well tolerated in patients with refractory advanced solid tumors. The results of this trial warrant further clinical investigation. Clin Cancer Res; 17(24); 7754–64. ©2011 AACR." @default.
• W2097574458 created "2016-06-24" @default.
• W2097574458 creator A5003423276 @default.
• W2097574458 creator A5005980104 @default.
• W2097574458 creator A5007307218 @default.
• W2097574458 creator A5037497042 @default.
• W2097574458 creator A5045588447 @default.
• W2097574458 creator A5046995957 @default.
• W2097574458 creator A5068642720 @default.
• W2097574458 creator A5069559870 @default.
• W2097574458 creator A5090068456 @default.
• W2097574458 creator A5091526303 @default.
• W2097574458 date "2011-12-15" @default.
• W2097574458 modified "2023-09-27" @default.
• W2097574458 title "A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors" @default.
• W2097574458 cites W1490349467 @default.
• W2097574458 cites W1555647603 @default.
• W2097574458 cites W1985995844 @default.
• W2097574458 cites W1998971866 @default.
• W2097574458 cites W2019573100 @default.
• W2097574458 cites W2023568503 @default.
• W2097574458 cites W2045115099 @default.
• W2097574458 cites W2048097275 @default.
• W2097574458 cites W2071572077 @default.
• W2097574458 cites W2072264945 @default.
• W2097574458 cites W2076668534 @default.
• W2097574458 cites W2098451955 @default.
• W2097574458 cites W2116350465 @default.
• W2097574458 cites W2120795894 @default.
• W2097574458 cites W2125519805 @default.
• W2097574458 cites W2138896702 @default.
• W2097574458 cites W2139073495 @default.
• W2097574458 cites W2139248078 @default.
• W2097574458 cites W2155679349 @default.
• W2097574458 cites W2159759971 @default.
• W2097574458 cites W2205149318 @default.
• W2097574458 cites W2240219703 @default.
• W2097574458 cites W2241628017 @default.
• W2097574458 cites W2241934631 @default.
• W2097574458 cites W2246590687 @default.
• W2097574458 cites W2247460471 @default.
• W2097574458 cites W2254573112 @default.
• W2097574458 cites W2279974145 @default.
• W2097574458 cites W2281242723 @default.
• W2097574458 cites W2417613024 @default.
• W2097574458 cites W2469964205 @default.
• W2097574458 cites W2530681482 @default.
• W2097574458 cites W3009126648 @default.
• W2097574458 cites W1948497307 @default.
• W2097574458 doi "https://doi.org/10.1158/1078-0432.ccr-11-1002" @default.
• W2097574458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21976535" @default.
• W2097574458 hasPublicationYear "2011" @default.
• W2097574458 type Work @default.
• W2097574458 sameAs 2097574458 @default.
• W2097574458 citedByCount "87" @default.
• W2097574458 countsByYear W20975744582012 @default.
• W2097574458 countsByYear W20975744582013 @default.
• W2097574458 countsByYear W20975744582014 @default.
• W2097574458 countsByYear W20975744582015 @default.
• W2097574458 countsByYear W20975744582016 @default.
• W2097574458 countsByYear W20975744582017 @default.
• W2097574458 countsByYear W20975744582018 @default.
• W2097574458 countsByYear W20975744582019 @default.
• W2097574458 countsByYear W20975744582020 @default.
• W2097574458 countsByYear W20975744582021 @default.
• W2097574458 crossrefType "journal-article" @default.
• W2097574458 hasAuthorship W2097574458A5003423276 @default.
• W2097574458 hasAuthorship W2097574458A5005980104 @default.
• W2097574458 hasAuthorship W2097574458A5007307218 @default.
• W2097574458 hasAuthorship W2097574458A5037497042 @default.
• W2097574458 hasAuthorship W2097574458A5045588447 @default.
• W2097574458 hasAuthorship W2097574458A5046995957 @default.
• W2097574458 hasAuthorship W2097574458A5068642720 @default.
• W2097574458 hasAuthorship W2097574458A5069559870 @default.
• W2097574458 hasAuthorship W2097574458A5090068456 @default.
• W2097574458 hasAuthorship W2097574458A5091526303 @default.
• W2097574458 hasConcept C111113717 @default.
• W2097574458 hasConcept C112705442 @default.
• W2097574458 hasConcept C126322002 @default.
• W2097574458 hasConcept C197934379 @default.
• W2097574458 hasConcept C22979827 @default.
• W2097574458 hasConcept C2777063308 @default.
• W2097574458 hasConcept C2777288759 @default.
• W2097574458 hasConcept C2778375690 @default.
• W2097574458 hasConcept C2778570526 @default.
• W2097574458 hasConcept C2780852908 @default.
• W2097574458 hasConcept C2780873365 @default.
• W2097574458 hasConcept C29730261 @default.
• W2097574458 hasConcept C71924100 @default.
• W2097574458 hasConcept C98274493 @default.
• W2097574458 hasConceptScore W2097574458C111113717 @default.
• W2097574458 hasConceptScore W2097574458C112705442 @default.
• W2097574458 hasConceptScore W2097574458C126322002 @default.
• W2097574458 hasConceptScore W2097574458C197934379 @default.
• W2097574458 hasConceptScore W2097574458C22979827 @default.
• W2097574458 hasConceptScore W2097574458C2777063308 @default.
• W2097574458 hasConceptScore W2097574458C2777288759 @default.
• W2097574458 hasConceptScore W2097574458C2778375690 @default.

• next